1. Investigating the Mechanisms of Graded Sensorimotor Precision Training in Adults With Chronic Nonspecific Low Back Pain: Protocol for a Causal Mediation Analysis of the RESOLVE Trial
- Author
-
Tasha R. Stanton, Matthew K Bagg, Hopin Lee, Benedict M Wand, Rodrigo R N Rizzo, Aidan G Cashin, James H. McAuley, Edel O'Hagan, G. Lorimer Moseley, Cashin, Aiden G, Lee, Hopin, Bagg, Matthew K, Wand, Benedict M, O'Hagan, Edel, Rizzo, Rodrigo RN, Stanton, Tasha R, Moseley, G Lorimer, and McAuley, James H
- Subjects
medicine.medical_specialty ,mechanism evaluation ,media_common.quotation_subject ,Computer applications to medicine. Medical informatics ,R858-859.7 ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Perception ,Health care ,Global health ,Protocol ,Medicine ,030212 general & internal medicine ,protocol ,mediation analysis ,media_common ,Protocol (science) ,business.industry ,General Medicine ,Low back pain ,Test (assessment) ,Clinical trial ,chronic low back pain ,Pain catastrophizing ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Background Chronic low back pain (CLBP) is a global health problem associated with an increasing burden on individuals, health care systems, and society. Common treatments for people with CLBP produce, on average, small short-term improvements in pain and function compared with minimal care. The RESOLVE trial randomly allocated 276 people with CLBP to a new complex treatment strategy, pain education integrated with graded sensorimotor precision training (RESOLVE), or a sham control. The RESOLVE treatment was developed within a theoretical framework to target possible treatment mechanisms associated with CLBP development and persistence. Objective This protocol describes the planned evaluation of these proposed treatment mechanisms. Improved understanding of the mechanisms underpinning the RESOLVE treatment may guide its refinement and implementation. Methods We will use causal mediation analysis to evaluate the proposed treatment mechanisms, including pain self-efficacy, back beliefs, pain catastrophizing, kinesiophobia, back perception, tactile acuity, and movement coordination. The primary outcomes are pain intensity and function at 18 weeks following allocation. Data were collected blind to allocation and hypotheses at baseline (mediators, outcomes, confounders), end of treatment (mediators), and at 18 weeks following allocation (outcomes). We will test the robustness of our findings by conducting planned sensitivity analyses. Results Ethical approval was granted by the University of New South Wales Human Research Ethics Committee (HC15357). A total of 276 participants have been recruited from primary care practices and the community in Sydney, Australia. Conclusions The RESOLVE treatment constitutes a new paradigm for CLBP management with potentially wide-reaching implications. This mechanistic evaluation will provide evidence for the hypothesized treatment mechanisms and help explain why the treatment strategy did or did not have an effect on patient-reported outcomes. These results will help guide the treatment refinement and implementation. Trial Registration Australian and New Zealand Clinical Trials Registry ACTRN12615000610538; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368619&isReview=true International Registered Report Identifier (IRRID) DERR1-10.2196/26053
- Published
- 2021